This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Dec 14, 2021
by Zacks Equity Research
Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $248.53, moving +1.8% from the previous trading session.
Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal
by Zacks Equity Research
Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug
by Zacks Equity Research
With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
by Zacks Equity Research
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.
Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19
by Zacks Equity Research
The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.
AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label
by Zacks Equity Research
AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.
Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids
by Zacks Equity Research
With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.
Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
by Zacks Equity Research
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.
Top Research Reports for Mastercard, Pfizer & Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and NIKE, Inc. (NKE).
Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down
by Zacks Equity Research
Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.
Lilly (LLY) Up 4.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
by Zacks Equity Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
3 Big Pharma Outperformers to Watch Out For in the Near Term
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint
by Zacks Equity Research
Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.
Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm
by Zacks Equity Research
Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.
Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan
by Zacks Equity Research
Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.
Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.
Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines
by Zacks Equity Research
Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.
Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially